Update on Generalized Pustular Psoriasis
DOI:
https://doi.org/10.20344/amp.22672Keywords:
Antibodies, Monoclonal, Humanized/therapeutic use, Interleukin /therapeutic use, Psoriasis/drug therapyAbstract
Generalized pustular psoriasis (GPP) is a rare but severe inflammatory skin disease characterized by the eruption of widespread sterile pustules, often accompanied by systemic inflammation. Although GPP can coexist with plaque psoriasis, it is increasingly recognized as a distinct entity with unique clinicopathological, immunologic, and genetic features. The dysregulated IL-36 pathway, including mutations in the IL36RN gene, is implicated in GPP pathogenesis, providing a molecular basis for targeted therapies. Diagnosing GPP requires a comprehensive evaluation, including clinical presentation, potential triggers, patient history, histopathologic findings, and laboratory results. Disease severity must be assessed through both cutaneous symptoms and systemic involvement, as GPP flares can lead to life-threatening complications such as sepsis and multi-organ failure. Historically, GPP treatment primarily relied on therapies approved for plaque psoriasis, despite their limited specificity for this condition. Recent advances in understanding the molecular mechanisms of GPP, particularly the central role of interleukin-36 pathway, have led to the development of targeted therapies for this rare condition. Currently, spesolimab is the only therapy specifically approved for treating GPP flares in adolescents and adults, in both Europe and the United States of America. However, the management of GPP remains complex and challenging. This narrative review provides an overview of the epidemiology, pathophysiology, clinical features, comorbidities, and evolving therapeutic strategies for GPP.
Downloads
References
Marrakchi S, Puig L. Pathophysiology of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:13-9. DOI: https://doi.org/10.1007/s40257-021-00655-y
Navarini AA, Burden AD, Capon F, Mrowietz U, Puig L, Köks S, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1792-9. DOI: https://doi.org/10.1111/jdv.14386
Choon SE, Navarini AA, Pinter A. Clinical course and characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:21-9. DOI: https://doi.org/10.1007/s40257-021-00654-z
Armstrong AW, Elston CA, Elewski BE, Ferris LK, Gottlieb AB, Lebwohl MG et al. Generalized pustular psoriasis: a consensus statement from the National Psoriasis Foundation. J Am Acad Dermatol. 2024;90:727- 30. DOI: https://doi.org/10.1016/j.jaad.2023.09.080
Prinz JC, Choon SE, Griffiths CE, Merola JF, Morita A, Ashroft DM, et al. Prevalence, comorbidities and mortality of generalized pustular psoriasis: a literature review. J Eur Acad Dermatol Venereol. 2023;37:256-73. DOI: https://doi.org/10.1111/jdv.18720
Fujita H, Gooderham M, Romiti R. Diagnosis of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:31-8. DOI: https://doi.org/10.1007/s40257-021-00652-1
Rivera-Díaz R, Daudén E, Carrascosa JM, Cueva P de la, Puig L. Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment. Dermatol Ther. 2023;13:673-88. DOI: https://doi.org/10.1007/s13555-022-00881-0
Reynolds KA, Pithadia DJ, Lee EB, Clarey D, Liao W, Wu JJ. Generalized pustular psoriasis: a review of the pathophysiology, clinical manifestations, diagnosis, and treatment. Cutis. 2022;110:19-25. DOI: https://doi.org/10.12788/cutis.0579
Johnston A, Xing X, Wolterink L, Barnes DH, Yin Z, Reingold L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140:109-20. DOI: https://doi.org/10.1016/j.jaci.2016.08.056
Krueger J, Puig L, Thaçi D. Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:51-64. DOI: https://doi.org/10.1007/s40257-021-00658-9
Blair HA. Spesolimab: First approval. Drugs. 2022;82:1681-6. DOI: https://doi.org/10.1007/s40265-022-01801-4
Zheng M, Jullien D, Eyerich K. The prevalence and disease characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:5-12. DOI: https://doi.org/10.1007/s40257-021-00664-x
Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15:907- 19. DOI: https://doi.org/10.1080/1744666X.2019.1648209
Zhou J, Luo Q, Cheng Y, Wen X, Liu J. An update on genetic basis of generalized pustular psoriasis (Review). Int J Mol Med. 2021;47:118. DOI: https://doi.org/10.3892/ijmm.2021.4951
Torres T, Antunes J, Brasileiro A, Alves J, Bernardo D, Ramos J, et al. Clinical course and disease burden of patients with generalized pustular psoriasis in Portugal: a multicenter retrospective cohort study. J Dermatol Treat. 2024;35:1-6. DOI: https://doi.org/10.1080/09546634.2024.2345728
Iznardo H, Puig L. The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives. Expert Rev Clin Immunol. 2021;17:187-99. DOI: https://doi.org/10.1080/1744666X.2021.1886081
Iznardo H, Puig L. IL-1 family cytokines in inflammatory dermatoses: pathogenetic role and potential therapeutic implications. Int J Mol Sci. 2022;23:9479. DOI: https://doi.org/10.3390/ijms23169479
Bachelez H. Pustular psoriasis: the dawn of a new era. Acta Derm Venereol. 2020;100:87-92. DOI: https://doi.org/10.2340/00015555-3388
Sachen KL, Arnold Greving CN, Towne JE. Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions. Cytokine. 2022;156:155897. DOI: https://doi.org/10.1016/j.cyto.2022.155897
Mahil SK, Catapano M, Di Meglio P, Dand N, Ahlfors H, Carr IM, et al. An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target. Sci Transl Med. 2017;9:eaan2514. DOI: https://doi.org/10.1126/scitranslmed.aan2514
Baum P, Visvanathan S, Garcet S, Roy J, Schmid R, Bossert S, et al. Pustular psoriasis: molecular pathways and effects of spesolimab in generalized pustular psoriasis. J Allergy Clin Immunol. 2022;149:1402- 12. DOI: https://doi.org/10.1016/j.jaci.2021.09.035
Fukaura R, Akiyama M. Targeting IL-36 in inflammatory skin diseases. BioDrugs. 2023;37:279-93. DOI: https://doi.org/10.1007/s40259-023-00587-5
Menter A, Van Voorhees AS, Hsu S. Pustular psoriasis: a narrative review of recent developments in pathophysiology and therapeutic options. Dermatol Ther. 2021;11:1917-29. DOI: https://doi.org/10.1007/s13555-021-00612-x
Genovese G, Moltrasio C, Cassano N, Maronese CA, Vena GA, Marzano AV. Pustular psoriasis: from pathophysiology to treatment. Biomedicines. 2021;9:1746. DOI: https://doi.org/10.3390/biomedicines9121746
Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45:1235-70. DOI: https://doi.org/10.1111/1346-8138.14523
Teshima R, Saito-Sasaki N, Sawada Y. Generalized pustular psoriasis and systemic organ dysfunctions. Int J Mol Sci. 2024;25:6270. DOI: https://doi.org/10.3390/ijms25116270
Lu J, Shi Y. A review of disease burden and clinical management for generalized pustular psoriasis in China. Expert Rev Clin Immunol. 2022;18:1023-32. DOI: https://doi.org/10.1080/1744666X.2022.2118716
Burden AD, Bissonnette R, Lebwohl MG, Gloede T, Anatchkova M, Budhiarso I, et al. Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI). J Eur Acad Dermatol Venereol. 2023;37:1327-35. DOI: https://doi.org/10.1111/jdv.18999
Burden AD, Bachelez H, Choon SE, Marrakchi S, Tsai TF, Turki H, et al. The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity. Br J Dermatol. 2023;189:138-40. DOI: https://doi.org/10.1093/bjd/ljad071
Kearns DG, Chat VS, Zang PD, Han G, Wu JJ. Review of treatments for generalized pustular psoriasis. J Dermatol Treat. 2021;32:492-4. DOI: https://doi.org/10.1080/09546634.2019.1682502
Sheu JS, Divito SJ, Enamandram M, Merola JF. Dapsone therapy for pustular psoriasis: Case series and review of the literature. Dermatology. 2016;232:97-101. DOI: https://doi.org/10.1159/000431171
Jeon C, Nakamura M, Sekhon S, Yan D, Wu JJ, Liao W, et al. Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities. JAAD Case Rep. 2017;3:495-7. DOI: https://doi.org/10.1016/j.jdcr.2017.07.007
Bernardo D, Thaçi D, Torres T. Spesolimab for the treatment of generalized pustular psoriasis. Drugs. 2024;84:45-58. DOI: https://doi.org/10.1007/s40265-023-01988-0
Hsieh CY, Tsai TF. Clinical advances in biological therapy for generalized pustular psoriasis: a review. Expert Opin Biol Ther. 2024;24:37-50. DOI: https://doi.org/10.1080/14712598.2024.2309301
Saeki H, Terui T, Morita A, Sano S, Imafuku S, Asahina A, et al. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol. 2020;47:201-22. DOI: https://doi.org/10.1111/1346-8138.15196
Megna M, Camela E, Ruggiero A, Battista T, Martora F, Cacciapuoti S, et al. Use of biological therapies for the management of pustular psoriasis: a new era? Clin Cosmet Investig Dermatol. 2023;16:1677-90. DOI: https://doi.org/10.2147/CCID.S407812
Abduelmula A, Rankin BD, Sood S, Georgakopoulos JR, Mufti A, Vender R, et al. Management of adult generalized pustular psoriasis using biologics: a systematic review. J Am Acad Dermatol. 2023;89:417-9. DOI: https://doi.org/10.1016/j.jaad.2023.04.031
Hüffmeier U, Wätzold M, Mohr J, Schön MP, Mössner R. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol. 2014;170:202-4. DOI: https://doi.org/10.1111/bjd.12548
Skendros P, Papagoras C, Lefaki I, Giatromanolaki A, Kotsianidis I, Speletas M, et al. Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition. Br J Dermatol. 2017;176:212-5. DOI: https://doi.org/10.1111/bjd.14685
Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380:981-3. DOI: https://doi.org/10.1056/NEJMc1811317
Navarini AA, Prinz JC, Morita A, Tsai TF, Viguier MA, Li L, et al. Spesolimab improves patient-reported outcomes in patients with generalized pustular psoriasis: Results from the Effisayil 1 study. J Eur Acad Dermatol Venereol. 2023;37:730-6. DOI: https://doi.org/10.1111/jdv.18820
SPEVIGO® [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2024.
Morita A, Choon SE, Bachelez H, Anadkat MJ, Marrakchi S, Zheng M, et al. Design of EffisayilTM 2: a randomized, double-blind, placebocontrolled study of spesolimab in preventing flares in patients with generalized pustular psoriasis. Dermatol Ther. 2023;13:347-59. DOI: https://doi.org/10.1007/s13555-022-00835-6
Warren RB, Reich A, Kaszuba A, Placek W, Griffiths CE, Zhou J, et al. Imsidolimab, an anti-IL-36 receptor monoclonal antibody for the treatment of generalized pustular psoriasis: Results from the Phase 2 GALLOP trial. Br J Dermatol. 2023;189:161-9. DOI: https://doi.org/10.1093/bjd/ljad083
Pogorelov D, Tschesche A, Balakirski G, Hofmann SC. Generalized pustular psoriasis of pregnancy successfully treated with certolizumab pegol: a case report and literature review. Cureus. 2024;16:e59832. DOI: https://doi.org/10.7759/cureus.59832
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
